anti_endometrial Antibodies in Endometriosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-12-01

Study Completion Date

2023-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aims of this study is to asses the predictive value of serum anti\_endometrial antibodies in prediction of implantation rate in patient with endometriosis who undergoing intracytoplasmic sperm injection cycles.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Stimulated Versus Un-stimulated Intrauterine Insemination Cycles in Women With Endometriosis

NCT02470169

Subfertility

UNKNOWN PHASE3

A Liquid Biopsy Diagnostic Techniques for Endometriosis

NCT05749341

Liquid Biopsy Endometriosis

ENROLLING_BY_INVITATION

Relation Between Ethanol Sclerotherapy for Endometrioma Systemic Immune Milieu

NCT05470972

Endometriosis

COMPLETED EARLY_PHASE1

Efficacy of SN132D in Patients With Suspected Endometriosis

NCT05664828

Endometriosis

COMPLETED PHASE2

Prospective Study of the Outcomes of the Surgical Treatment of Deeply Infiltrating Endometriosis

NCT01105897

Endometriosis

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

prospective cohort study of infertile patients ( with endometriosis \& adenomyosis) who will undergo ICSI cycles at the assisted reproduction units,Obstetrics and Gynacology departments , South Valley University and Cairo University.

Initial evaluation: this will include:

1. Detailed history and clinical examination.
2. Ovarian reserve testing (serum AMH , basal serum FSH and basal AFC by US)
3. Uterine cavity examination ( by trasvaginal 3-dimentional ultrasound or office hysteroscopy)
4. routine investigations (Complete blood count, blood grouping , liver function tests , kidney function tests , prothrombin time , prothrombin concentration , serum bloog sugar)
5. Evaluation of male factor (husbnad semen analysis)

* Eligible women will undergo :

* Transvaginal ultrasound for evaluation of endometriosis ( shape , size , unilateral or bilateral , unilocular or bilocular )
* Perform laparscopy for confirmation of endometriosis using revised ASM classification for endometriosis
* Measurement of serum anti\_endometrial antibodies :
* Take blood samples from patients to measure anti-endometrial antibody concentrations in the serum of women with endometriosis using human Endometrium Antibody, EMAb ELISA Kit .

Intracytoplasmic sperm injection (ICSI) gonadotrophin stimulation drugs will be used, individualization of stimulation dose and slight modifications will be done according to ovarian response. Proper protocol will be used. Baseline assessment of AFC by transvaginal scans wasill be performed by experienced gynaecologist using a 7.5 MHz vaginal probe 7-MHz (Samsung, Korea). Ovarian response monitoring to stimulation drug, estimation the doses of gonadotrophins required for follicular growing and maturation, assessment the stimulation time in days till time of ovum pick-up, and the number and quality of oocytes obtained will be recorded in and analysed at the end of the study. When 3-4 follicles acquired \>18 mm ,triggering of ovulation will be done using human chorionic gonadotrophins 36 hours prior to pick-up of oocytes. after oocyte retrieval ICSI procedure will be done for all cases. embryos will be transferred to each mother on day 3 or day 5 according to embryos quality and remaining of good quality embryos will be frozen for subsequent transfer. Luteal support started in day of ova pick up till date of pregnancy test (14 days post embryos transfer)

Research outcome measures:

a. Primary (main):

* assess the predictive value of serum antiendometrial antibodies in prediction of implantation rate in patient with endometriosis who undergoing intracytoplasmic sperm injection cycles b. Secondary (subsidiary):
* to find correlation between serum anti-endometrial antibodies and egg quality retrieved

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Anti-endometrial Antibodies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

serum anti-endometrial antibodies

\- Take blood samples from patients to measure anti-endometrial antibody concentrations in the serum of women with endometriosis using human Endometrium Antibody, EMAb ELISA Kit .This assay employs the qualitative enzyme immunoassay technique

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- Patients will be enrolled in this study if they fulfill the following criteria:

1. infertile patients (with endometriosis \& adenomyosis ) who will undergo ICSI cycles
2. Age: 18-35 years.
3. Body mass index (BMI): ≤ 30.
4. primary or secondary infirtility. 5 duration of infertility less than 10 years

6\. results of semen examination of patients' husbands will be within the World Health Organization (WHO) reference range.

Exclusion Criteria

Patients will not be eligible for this study if:

1\. gynecological problem e.g. uterine polyp, hydrosalpinx will be excluded 2. Male factor: Abnormal sperm morphology;(globozoospermia and pin- point sperm) will be excluded 3 . congenital structural abnormalities of the reproductive tract, pelvic tuberculosis, ovarian tumour, hyperprolactinaemia, adrenal disease, thyroid disease or other endocrine disease,

\-

Minimum Eligible Age

15 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No